{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T03:17:45Z","timestamp":1769051865606,"version":"3.49.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioinform."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Colon cancer is a common disease, treated with few chemotherapeutic agents with similar treatment sequencing despite its heterogeneity. A significant proportion of patients are diagnosed with metastasis, and resistance to antineoplastic drugs is associated with disease progression and therapeutic failure. It is known that the tumor microenvironment plays an essential role in cancer progression, contributing to processes that may be associated with therapeutic resistance mechanisms in colon cancer. In this study, we aim to identify a gene expression signature and its relationship with immune cell infiltration in colon cancer, contributing to the identification of potential resistance biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      An\n                      <jats:italic>in silico<\/jats:italic>\n                      study was conducted using RNA-seq data from The Cancer Genome Atlas Program (TCGA) samples, subdivided into two groups (treatment-resistant and non-resistant), taking into account the molecular subgroups (CMS1, CMS2, CMS3, and CMS4). The following algorithms were used: i.\n                      <jats:italic>Limma<\/jats:italic>\n                      was applied to identify differentially expressed genes; ii. WGCNA was applied to construct co-expression networks; iii. CIBERSORT was applied to estimate the proportion of infiltrating immune cells; and iv. TIMER was applied to explore the relationship between core genes and immune cell content.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty differentially expressed genes (DEGs) were found, with 18 related to the group considered resistant to oncologic treatment and presenting poorer overall survival. T CD4 memory resting cells and M0 and M2 macrophages were found in more significant proportions in the analyzed samples and more infiltrated in the tumor microenvironment, the higher the expression of some of these resistance DEGs. Additionally, these genes correlate with biological aspects of neuronal differentiation, axogenesis, and synaptic transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The gene expression signature suggests the presence of differentially expressed synaptic membrane genes, which may be involved in neuronal pathways that influence the tumor microenvironment, potentially serving as future biomarkers. Furthermore, the presence of M0 and M2 macrophages and T CD4 memory resting cells suggests a potential interaction that may play a role in therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fbinf.2025.1674179","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:55:32Z","timestamp":1761720932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene expression profile in colon cancer therapeutic resistance and its relationship with the tumor microenvironment"],"prefix":"10.3389","volume":"5","author":[{"given":"Priscila Galv\u00e3o","family":"Doria","sequence":"first","affiliation":[]},{"given":"Gisele Vieira","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Vanessa Dybal","family":"Bertoni","sequence":"additional","affiliation":[]},{"given":"Roberto de Souza Batista dos","family":"Santos","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Ara\u00fajo-Pereira","sequence":"additional","affiliation":[]},{"given":"Clarissa","family":"Gurgel","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3390\/cancers12040806","article-title":"Are synapse-like structures a possible way for crosstalk of cancer with its microenvironment?","volume":"12","author":"Alekseenko","year":"2020","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2249.2011.04515.x","article-title":"Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment","volume":"167","author":"Allavena","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","article-title":"The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages","volume":"66","author":"Allavena","year":"2008","journal-title":"Crit. Rev. Oncology\/Hematology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","article-title":"Nociceptor neurons affect cancer immunosurveillance","volume":"611","author":"Balood","year":"2022","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ccell.2017.02.005","article-title":"Nerve dependence: from regeneration to cancer","volume":"31","author":"Boilly","year":"2017","journal-title":"Cancer Cell"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/path.4212","article-title":"Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer","volume":"231","author":"Budinska","year":"2013","journal-title":"J. Pathology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.1158\/0008-5472.CAN-12-0764","article-title":"Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of RET tyrosine kinase receptor","volume":"72","author":"Cavel","year":"2012","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"B9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2346094","DOI":"10.1001\/jamanetworkopen.2023.46094","article-title":"Liver metastases and immune checkpoint inhibitor efficacy in patients with refractory metastatic colorectal cancer","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.3390\/cancers12092350","article-title":"Molecular targets for the treatment of metastatic colorectal cancer","volume":"12","author":"Cohen","year":"2020","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1158\/2326-6066.CIR-14-0161","article-title":"The immunological synapse","volume":"2","author":"Dustin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"16618","DOI":"10.1038\/s41598-017-16747-x","article-title":"CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models","volume":"7","author":"Eide","year":"2017","journal-title":"Sci. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"B17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer Drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"B18","first-page":"153","article-title":"Adhesion-dependent multicellular drug resistance","volume":"14","author":"Green","year":"1999","journal-title":"Anti-cancer Drug Des."},{"key":"B19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41416-020-01140-9","article-title":"FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial","volume":"124","author":"Heinemann","year":"2021","journal-title":"Br. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.cell.2014.06.049","article-title":"Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin","volume":"158","author":"Hoadley","year":"2014","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","first-page":"D355","DOI":"10.1093\/nar\/gkp896","article-title":"KEGG for representation and analysis of molecular networks involving diseases and drugs","volume":"38","author":"Kanehisa","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0003744","DOI":"10.1371\/journal.pntd.0003744","article-title":"Trypanosomiasis-induced megacolon illustrates How myenteric neurons modulate the risk for Colon cancer in rats and humans","volume":"9","author":"Kannen","year":"2015","journal-title":"PLOS Neglected Trop. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","article-title":"Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy","volume":"99","author":"Komohara","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinforma."},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12094-021-02666-x","article-title":"Nerve growth factor orchestrates NGAL and matrix metalloproteinases activity to promote colorectal cancer metastasis","volume":"24","author":"Lei","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.ajpath.2013.05.021","article-title":"RAMP1 is a direct NKX3.1 target gene Up-Regulated in prostate cancer that promotes tumorigenesis","volume":"183","author":"Logan","year":"2013","journal-title":"Am. J. Pathology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/annonc\/mdy033","article-title":"European cancer mortality predictions for the year 2018 with focus on colorectal cancer","volume":"29","author":"Malvezzi","year":"2018","journal-title":"Ann. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","article-title":"Gene expression classification of Colon cancer into molecular subtypes: characterization, validation, and prognostic value","volume":"10","author":"Marisa","year":"2013","journal-title":"PLoS Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0189545","DOI":"10.1371\/journal.pone.0189545","article-title":"\u03b1II-Spectrin in T cells is involved in the regulation of cell-cell contact leading to immunological synapse formation","volume":"12","author":"Meissner","year":"2017","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1146\/annurev-med-070119-120448","article-title":"Use of circulating cell-free DNA to guide precision medicine in patients with colorectal cancer","volume":"72","author":"Morris","year":"2021","journal-title":"Annu. Rev. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1073\/pnas.081626898","article-title":"Role of tumor\u2013host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors","volume":"98","author":"Pluen","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.3390\/ijms23052782","article-title":"Molecular mechanisms of tumor immunomodulation in the microenvironment of colorectal cancer","volume":"23","author":"Plundrich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ijc.28387","article-title":"Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial\u2010to\u2010mesenchymal transition","volume":"134","author":"Roepman","year":"2014","journal-title":"Int. J. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nm.3175","article-title":"A colorectal cancer classification system that associates cellular phenotype and responses to therapy","volume":"19","author":"Sadanandam","year":"2013","journal-title":"Nat. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1755-8794-5-66","article-title":"Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines","volume":"5","author":"Schlicker","year":"2012","journal-title":"BMC Med. Genomics"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0246160","DOI":"10.1371\/journal.pone.0246160","article-title":"Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: a retrospective observational study using an administrative database","volume":"16","author":"Shinozaki","year":"2021","journal-title":"PLOS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.3174","article-title":"Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions","volume":"19","author":"Sousa","year":"2013","journal-title":"Nat. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-0716-0301-7_7","article-title":"Profiling cell type abundance and expression in bulk tissues with CIBERSORTx","volume":"2117","author":"Steen","year":"2020","journal-title":"Em"},{"key":"B47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1590\/S0100-879X2008005000008","article-title":"Intrinsic denervation of the colon is associated with a decrease of some colonic preneoplastic markers in rats treated with a chemical carcinogen","volume":"41","author":"Vesp\u00facio","year":"2008","journal-title":"Braz. J. Med. Biol. Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-023-00857-y","article-title":"Perineural invasion in colorectal cancer: mechanisms of action and clinical relevance","volume":"47","author":"Wang","year":"2024","journal-title":"Cell. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.12017","article-title":"How the immune system talks to itself: the varied role of synapses","volume":"251","author":"Xie","year":"2013","journal-title":"Immunol. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0292452","DOI":"10.1371\/journal.pone.0292452","article-title":"RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma","volume":"18","author":"Xie","year":"2023","journal-title":"PLOS ONE"},{"key":"B54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41568-019-0237-2","article-title":"Nerves in cancer","volume":"20","author":"Zahalka","year":"2020","journal-title":"Nat. Rev. Cancer"}],"container-title":["Frontiers in Bioinformatics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1674179\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:55:33Z","timestamp":1761720933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbinf.2025.1674179\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":54,"alternative-id":["10.3389\/fbinf.2025.1674179"],"URL":"https:\/\/doi.org\/10.3389\/fbinf.2025.1674179","relation":{},"ISSN":["2673-7647"],"issn-type":[{"value":"2673-7647","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"article-number":"1674179"}}